Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

被引：0
|
作者：
Moura, Filipe A.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John
Gause-nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13182
引用
收藏
页数：3
相关论文
共 50 条
  • [1] DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
    Furtado, Remo Holanda de Mendonca
    Bonaca, Marc
    Raz, Itamar
    Zelniker, Thomas
    Mosenzon, Ofri
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren
    Wilding, John P. H.
    Ruff, Christian
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc
    Wiviott, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1 - 1
  • [2] The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
    Schechter, Meir
    Wiviott, Stephen D.
    Raz, Itamar
    Goodrich, Erica L.
    Cahn, Avivit
    Langkilde, Anna Maria
    Gause-Nilsson, Ingrid A.
    Sabatine, Marc S.
    Mosenzon, Ofri
    CIRCULATION, 2022, 146
  • [3] Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
    Cahn, Avivit
    Raz, Itamar
    Bonaca, Marc
    Mosenzon, Ofri
    Murphy, Sabina A.
    Yanuv, Ilan
    Rozenberg, Aliza
    Wilding, John P. H.
    Bhatt, Deepak L.
    McGuire, Darren K.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Jermendy, Gyorgy
    Hadjadj, Samy
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    Leiter, Lawrence A.
    DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1357 - 1368
  • [4] Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
    Zelniker, Thomas A.
    Bonaca, Marc P.
    Furtado, Remo H. M.
    Mosenzon, Ofri
    Kuder, Julia F.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Budaj, Andrzej
    Kiss, Robert G.
    Padilla, Francisco
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2020, 141 (15) : 1227 - 1234
  • [5] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Cahn, Avivit
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Heerspink, Hiddo J. L.
    Zelniker, Thomas A.
    Dwyer, Jamie P.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Kato, Eri T.
    Gause-Nilson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : 606 - 617
  • [6] Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
    Kolkailah, Ahmed A.
    Wiviott, Stephen D.
    Raz, Itamar
    Murphy, Sabina A.
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Sabatine, Marc S.
    McGuire, Darren K.
    DIABETES CARE, 2022, 45 (02) : E27 - E29
  • [7] Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
    Oyama, K.
    Raz, I.
    Cahn, A.
    Goodrich, E.
    Bhatt, D.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Gause-Nilsson, I.
    Mosenzon, O.
    Sabatine, M.
    Wiviott, S.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2961 - 2961
  • [8] Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
    Oyama, Kazuma
    Raz, Itamar
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Park, Kyong-Soo
    Goudev, Assen
    Diaz, Rafael
    Spinar, Jindrich
    Gause-Nilsson, Ingrid A. M.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Wiviott, Stephen D.
    EUROPEAN HEART JOURNAL, 2022, 43 (31) : 2958 - 2967
  • [9] Pioglitazone in patients with type 2 diabetes: A sub-analysis of patients meeting criteria for the metabolic syndrome
    Lester, JW
    Fernandes, AW
    DIABETES, 2004, 53 : A134 - A134
  • [10] Effect of dapagliflozin on atrial fibrillation/flutter in patients with Type 2 Diabetes mellitus: insights from the DECLARE-TIMI 58 trial
    Zelniker, T.
    Bonaca, M.
    Mosenzon, O.
    Kuder, J.
    Murphy, S.
    Remo, F.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Budaj, A.
    Kiss, G.
    Padilla, F.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Raz, I.
    Sabatine, M.
    Wiviott, S.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S158 - S158
12345